Accumulating evidence supports the prognostic and predictive role of the host immune response in early stage breast cancers, especially in oestrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative (i.e. triple negative) breast cancers (TNBCs) 5, 6, 7. This evidence concerns the gene ERBB2 and breast carcinoma.